title: HSP90 Inhibitor SNX5422/2112 Targets the Dysregulated Signal and Transcription Factor Network and Malignant Phenotype of Head and Neck Squamous Cell Carcinoma.
abstract: Heat shock protein 90 (HSP90) is a chaperone protein that stabilizes proteins involved in oncogenic and therapeutic resistance pathways of epithelial cancers, including head and neck squamous cell carcinomas (HNSCCs). Here, we characterized the molecular, cellular, and preclinical activity of HSP90 inhibitor SNX5422/2112 in HNSCC overexpressing HSP90. SNX2112 inhibited proliferation, induced G2/M block, and enhanced cytotoxicity, chemosensitivity, and radiosensitivity between 25 and 250 nM in vitro. SNX2112 showed combinatorial activity with paclitaxel in wild-type (wt) TP53-deficient and cisplatin in mutant (mt) TP53 HNSCC lines. SNX2112 decreased expression or phosphorylation of epidermal growth factor receptor (EGFR), c-MET, v-akt murine thymoma viral oncogene homolog 1 (AKT), extracellular signal-regulated kinases (ERK) 1 and 2, inhibitor κB kinase, and signal transducer and transcription factor 3 (STAT3), corresponding downstream nuclear factor κB, activator protein-1, and STAT3 reporter genes, and target oncogenes and angiogenic cytokines. Furthermore, SNX2112 enhanced re-expression of TP53 and targets p21WAF1 and PUMA, while TP53 inhibitor Pifithrin or siRNA attenuated the antiproliferative activity of SNX2112 in wtTP53 HNSCC in vitro. Prodrug SNX5422 similarly down-modulated key signal targets, enhanced TP53 expression and apoptosis, and inhibited proliferation, angiogenesis, and tumorigenesis in a wtTP53-deficient HNSCC xenograft model. Thus, HSP90 inhibitor SNX5422/2112 broadly modulates multiple key nodes within the dysregulated signaling network, with corresponding effects upon the malignant phenotype. Our data support investigation of SNX5422/2112 in combination with paclitaxel, cisplatin, and radiotherapy in HNSCC with different TP53 status.
authors.affiliation: Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD.
authors.forename: Jay A
authors.initials: JA
authors.lastname: Friedman
authors.forename: Stephanie C
authors.initials: SC
authors.lastname: Wise
authors.forename: Michael
authors.initials: M
authors.lastname: Hu
authors.forename: Chris
authors.initials: C
authors.lastname: Gouveia
authors.forename: Robert
authors.initials: R
authors.lastname: Vander Broek
authors.forename: Christian
authors.initials: C
authors.lastname: Freudlsperger
authors.forename: Vishnu R
authors.initials: VR
authors.lastname: Kannabiran
authors.forename: Pattatheyil
authors.initials: P
authors.lastname: Arun
authors.forename: James B
authors.initials: JB
authors.lastname: Mitchell
authors.forename: Zhong
authors.initials: Z
authors.lastname: Chen
authors.forename: Carter
authors.initials: C
authors.lastname: Van Waes
references.citation: Oncol Res. 2009;18(5-6):229-42
references.pmid: 20225761
references.citation: Neoplasia. 2012 Aug;14(8):670-7
references.pmid: 22952420
references.citation: Expert Opin Ther Targets. 2011 Jan;15(1):63-74
references.pmid: 21110697
references.citation: Clin Cancer Res. 2011 Jan 1;17(1):122-33
references.pmid: 21208906
references.citation: Cancer Res. 2011 Nov 1;71(21):6867-77
references.pmid: 21933882
references.citation: Clin Cancer Res. 2011 Nov 1;17(21):6831-9
references.pmid: 21908572
references.citation: Eur J Cancer. 2010 Jan;46(2):340-7
references.pmid: 19945858
references.citation: J Mol Med (Berl). 2004 Aug;82(8):488-99
references.pmid: 15168026
references.citation: Mol Cancer Ther. 2008 Jul;7(7):1949-60
references.pmid: 18645005
references.citation: J Biol Chem. 2007 May 11;282(19):14626-34
references.pmid: 17363365
references.citation: J Cell Physiol. 2013 Jan;228(1):130-41
references.pmid: 22566192
references.citation: Clin Cancer Res. 2008 Jan 1;14(1):240-8
references.pmid: 18172276
references.citation: Head Neck. 2000 Dec;22(8):748-59
references.pmid: 11084634
references.citation: Curr Opin Pharmacol. 2009 Aug;9(4):389-95
references.pmid: 19570715
references.citation: Semin Oncol. 2008 Jun;35(3):286-97
references.pmid: 18544443
references.citation: Cancer Res. 2001 Aug 1;61(15):5911-8
references.pmid: 11479233
references.citation: Head Neck. 2003 Aug;25(8):654-61
references.pmid: 12884349
references.citation: Cancer Res. 1995 Oct 15;55(20):4623-6
references.pmid: 7553639
references.citation: J Med Chem. 2009 Jul 23;52(14):4288-305
references.pmid: 19552433
references.citation: Science. 2011 Aug 26;333(6046):1157-60
references.pmid: 21798893
references.citation: Cancer Res. 2009 Apr 1;69(7):3021-31
references.pmid: 19318576
references.citation: Clin Cancer Res. 2009 Oct 1;15(19):5974-84
references.pmid: 19789307
references.citation: Clin Cancer Res. 2005 May 15;11(10):3889-96
references.pmid: 15897590
references.citation: Blood. 2009 Jan 22;113(4):846-55
references.pmid: 18948577
references.citation: N Engl J Med. 2008 Sep 11;359(11):1116-27
references.pmid: 18784101
references.citation: Clin Cancer Res. 2001 Jun;7(6):1812-20
references.pmid: 11410524
references.citation: Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11598-603
references.pmid: 11504915
references.citation: Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6568-78
references.pmid: 18006756
references.citation: Genome Biol. 2007;8(5):R78
references.pmid: 17498291
references.citation: Oral Oncol. 2009 Oct;45(10):e155-60
references.pmid: 19586795
references.citation: Clin Cancer Res. 2008 Jul 1;14(13):4175-85
references.pmid: 18593997
references.citation: Nat Clin Pract Oncol. 2008 Sep;5(9):521-30
references.pmid: 18594498
references.citation: Clin Cancer Res. 2001 Feb;7(2):435-42
references.pmid: 11234901
references.citation: N Engl J Med. 2007 Dec 20;357(25):2552-61
references.pmid: 18094376
references.citation: Chem Biol. 2010 Jul 30;17(7):686-94
references.pmid: 20659681
references.citation: Clin Cancer Res. 2007 Jun 1;13(11):3182-90
references.pmid: 17545521
references.citation: Clin Cancer Res. 2009 Apr 1;15(7):2361-72
references.pmid: 19318490
references.citation: Int J Cancer. 2008 May 1;122(9):1987-98
references.pmid: 18172861
references.citation: Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):447-54
references.pmid: 19879702
references.citation: Mol Cancer Ther. 2006 Jan;5(1):8-19
references.pmid: 16432158
references.citation: Cell Cycle. 2010 Dec 15;9(24):4841-7
references.pmid: 21088498
references.citation: Nat Rev Cancer. 2010 Aug;10(8):537-49
references.pmid: 20651736
references.citation: Clin Cancer Res. 2009 Mar 1;15(5):1585-92
references.pmid: 19190133
references.citation: Head Neck. 2010 Apr;32(4):417-26
references.pmid: 19760794
references.citation: Semin Oncol. 2000 Aug;27(4 Suppl 8):39-43
references.pmid: 10952437
references.citation: Clin Cancer Res. 2007 Oct 1;13(19):5680-91
references.pmid: 17908957
references.citation: Cancer Discov. 2012 Aug;2(8):694-705
references.pmid: 22719020
references.citation: Cell Death Differ. 1999 Aug;6(8):773-80
references.pmid: 10467351
references.citation: Ann Oncol. 2009 Jan;20(1):84-90
references.pmid: 18669866
references.citation: Curr Pharm Des. 2013;19(3):347-65
references.pmid: 22920906
references.citation: Cell. 2012 May 11;149(4):807-18
references.pmid: 22579285
references.citation: Oncogene. 2009 Feb 26;28(8):1151-61
references.pmid: 19137016
references.citation: J Oral Pathol Med. 1998 Jan;27(1):18-22
references.pmid: 9466730
references.citation: Mol Pharmacol. 2008 Jun;73(6):1632-42
references.pmid: 18326051
references.citation: Int J Cancer. 2002 Jun 1;99(4):538-48
references.pmid: 11992543
references.citation: Int J Cancer. 2010 Mar 1;126(5):1216-25
references.pmid: 19662650
references.citation: Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1400-12
references.pmid: 16005577
references.citation: J Biol Chem. 2001 Nov 2;276(44):40583-90
references.pmid: 11507088
references.citation: N Engl J Med. 2006 Feb 9;354(6):567-78
references.pmid: 16467544